GlassScriptPhysician profile
Laura Emily Devor
NPI 1821241399
$6,178.06
in general payments reported to CMS, 2019-2025
25 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.84 · 2022: $124 · 2023: $481 · 2024: $4,511 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,193 · Travel and Lodging: $1,944 · Consulting Fee: $750 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.49 |
| Travel and Lodging | $1,943.83 |
| Consulting Fee | $750.00 |
| Education | $128.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $2,562.83 | 2024 | |
| Daiichi Sankyo INC. | $642.67 | 2024-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $614.62 | 2022-2025 | Lynparza, Tagrisso |
| Pfizer INC. | $353.61 | 2023-2024 | |
| Janssen Biotech, INC. | $314.81 | 2023-2025 | Darzalex, Tecvayli, Akeega |
| Novartis Pharmaceuticals Corporation | $191.08 | 2024 | |
| Mirati Therapeutics, INC. | $144.87 | 2023-2024 | Krazati |
| Abbvie INC. | $140.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $131.20 | 2023-2024 | Ojjaara |
| Novocure INC. | $130.79 | 2025 | Optune Gio |
| Boston Scientific Corporation | $121.60 | 2023-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Janssen Scientific Affairs, LLC | $121.29 | 2025 | Darzalex, Carvykti, Talvey |
| Adaptive Biotechnologies Corporation | $119.47 | 2025 | Clonoseq |
| Array Biopharma INC | $109.92 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Celgene Corporation | $89.97 | 2023-2025 | Reblozyl |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $66.43 | 2024-2025 | |
| Genmab U.S., INC. | $64.23 | 2023-2024 | Epkinly |
| Kite Pharma, INC. | $64.23 | 2024-2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $40.95 | 2024 | Opdualag, Krazati |
| Genentech USA, INC. | $38.97 | 2023-2024 | Venclexta, Lunsumio, Polivy |
| Seagen INC. | $32.22 | 2023 | Tukysa, Adcetris |
| Exelixis INC. | $24.44 | 2025 | Cabometyx |
| Incyte Corporation | $23.67 | 2025 | Jakafi |
| Kyowa Kirin, INC. | $18.85 | 2023 | Poteligeo |
| Tempus Ai, INC | $15.09 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Devor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.